Cambridge Investment Research Advisors
AYTU icon

Cambridge Investment Research Advisors’s AYTU BioPharma AYTU Stock Holding History

Cambridge Investment Research Advisors’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-70
Closed -$17K – 2711
2020
Q3 		$17K Hold
70
– – ﹤0.01% 2497
2020
Q2 		$20K Buy
70
+17
+32% +$5.15K ﹤0.01% 2423
2020
Q1 		$16K Buy
+53
New +$10.2K ﹤0.01% 2247

Other funds holding AYTU

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PSC
Piper Sandler & Co Minneapolis, Minnesota $135M AUM 0.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Cambridge Investment Research Advisors's AYTU Position: Q4 2020 in Review

Cambridge Investment Research Advisors sold out of AYTU BioPharma (AYTU) in Q4 2020, closing a stake of 70 shares — an estimated $17K sold.

Cambridge Investment Research Advisors first reported a position in AYTU in Q1 2020 and held it in 3 quarters. The position peaked at $20K in Q2 2020. 42 funds tracked by Wall St. Rank hold AYTU as of Q4 2020.

  • Cambridge Investment Research Advisors reported no remaining AYTU BioPharma position as of Q4 2020 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 70 AYTU BioPharma shares in Q4 2020, an estimated $17K.
  • Cambridge Investment Research Advisors first reported a position in AYTU BioPharma in Q1 2020 and held it in 3 quarters.
  • Cambridge Investment Research Advisors's AYTU BioPharma position peaked at $20K in Q2 2020.
  • 42 funds tracked by Wall St. Rank held AYTU BioPharma as of Q4 2020.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2020, filed 4 Feb 2021.